EP3177230A1 - Hybrid surgical mesh - Google Patents
Hybrid surgical meshInfo
- Publication number
- EP3177230A1 EP3177230A1 EP15830588.8A EP15830588A EP3177230A1 EP 3177230 A1 EP3177230 A1 EP 3177230A1 EP 15830588 A EP15830588 A EP 15830588A EP 3177230 A1 EP3177230 A1 EP 3177230A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mesh
- absorbable
- graft
- biodegradable
- hybrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004743 Polypropylene Substances 0.000 claims description 29
- 229920001155 polypropylene Polymers 0.000 claims description 20
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 19
- 239000000622 polydioxanone Substances 0.000 claims description 19
- -1 polypropylene Polymers 0.000 claims description 19
- 238000004090 dissolution Methods 0.000 claims description 6
- 208000012287 Prolapse Diseases 0.000 abstract description 13
- 238000001356 surgical procedure Methods 0.000 abstract description 11
- 230000035876 healing Effects 0.000 abstract description 8
- 230000005856 abnormality Effects 0.000 abstract description 6
- 238000005728 strengthening Methods 0.000 abstract description 2
- 210000001215 vagina Anatomy 0.000 description 26
- 239000004792 Prolene Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 206010016654 Fibrosis Diseases 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 230000003628 erosive effect Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 206010038084 Rectocele Diseases 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 210000003041 ligament Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 208000013823 pelvic organ prolapse Diseases 0.000 description 5
- 206010011803 Cystocele Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 206010048475 Bladder prolapse Diseases 0.000 description 3
- 206010019909 Hernia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010067505 Vulvovaginal adhesion Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000003356 suture material Substances 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000004989 Enterocele Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0004—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse
- A61F2/0031—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra
- A61F2/0036—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra implantable
- A61F2/0045—Support slings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
Definitions
- the present invention relates generally to implantable surgical meshes, and more particularly to hybrid surgical meshes that are partially bio-absorbable.
- Surgical meshes are used in a variety of surgical procedures.
- One particular application of surgical meshes is in the repair of pelvic organ prolapse (POP) in gynecologic surgery.
- POP occurs when tissues supporting the female pelvic organs become weak or stretched, and may result from a variety of conditions including pregnancy and childbirth, obesity, pelvic organ cancers, surgical removal of the uterus, and the like.
- the condition allows for organs, such as the bladder, uterus, or rectum, to bulge into the vagina and, in some extreme cases, to bulge past the vaginal opening.
- organs such as the bladder, uterus, or rectum
- approximately thirty five percent of women will experience POP in their lifetime, with two percent experiencing symptoms from the condition.
- Transvaginal meshes have previously been provided and have become the preferred method of treating POP.
- the standard transvaginal surgical graft configuration consists of a generally rectangular solid sheet of macroporous, non-absorbable monofilament polypropylene mesh with four arms that extend laterally outward, which graft is permanently implanted in the patient's vagina. Each arm of the graft is attached to the pelvic side wall and/or anatomical support structures. After implantation, the graft serves as a floor of support for the bladder and other organs, adding support to the anterior- lateral vaginal walls.
- Hybrid surgical mesh that is partially absorbable or
- the hybrid surgical mesh described herein generally comprises a central absorbable or biodegradable portion surrounded on at least its sides by a non-absorbable portion.
- the non-absorbable portion forms a hammock-like support structure for attaching the hybrid mesh within the patient's vagina and lateral pelvic walls in order to support a prolapsed region.
- the absorbable or biodegradable portion is sufficiently strong to provide support to the prolapsed region immediately following the surgical procedure to correct such prolapse, over time the central absorbable or biodegradable portion dissolves so as to leave only the non-absorbable portion.
- Such configuration provides the initial structural support required after the surgical procedure necessary to ensure healing and strengthening of the prolapsed region, while significantly reducing the risk of healing abnormalities or complications resulting in the central portion of the graft.
- an implantable graft comprising a hammock-like support structure configured for attachment to a patient's tissue formed of a non-absorbable mesh, and a biodegradable portion positioned at an interior portion of the non-absorbable mesh.
- a mesh for use in an implantable graft, comprising a biodegradable portion, and a nonabsorbable mesh attached to at least a portion of an outer perimeter edge of the biodegradable portion.
- FIG. 1 is a perspective view of a hybrid surgical mesh in accordance with certain aspects of an embodiment of the invention.
- FIG. 2 is a perspective view of a hybrid surgical mesh in accordance with further aspects of an embodiment of the invention.
- FIG. 3 is a perspective view of a hybrid surgical mesh in accordance with still further aspects of an embodiment of the invention.
- FIG. 4 is a photograph of a hybrid mesh formed for testing purposes and in accordance with certain aspects of an embodiment of the invention.
- FIG. 5 is a close-up photograph of another hybrid mesh formed for testing purposes and in accordance with certain aspects of an embodiment of the invention.
- Hybrid surgical meshes that are partially bio-absorbable or bio-degradable and partially non-degradable are described herein. While, for purposes of explanation, the hybrid surgical mesh set forth herein is described largely in the context of a surgical mesh used to repair POP, the invention is not limited to this context. Rather, the hybrid surgical meshes described herein may likewise be shaped for other medical implications such as, for example, rectal prolapse, enterocele, hernias, or such other medical conditions as may occur to those skilled in the art.
- a hybrid surgical graft 100 formed in accordance with the instant specification may avoid future complications associated with central portion graft erosion.
- FIG. 1 depicts a hybrid surgical graft 100 including a biodegradable central portion 190, with non- absorbable lateral portions 120 on each side of biodegradable central portion 190.
- one or more arms 132 and 134 extend outward from non-absorbable lateral portions 120 to attach the hybrid surgical graft 100 to the pelvic sidewall.
- Hybrid surgical graft 100 also generally has an extended portion at the anterior end, which can be cut to fit the length of the patient's vagina.
- hybrid surgical graft 100 may be generally about 5 centimeters wide by 10 centimeters long, and arms 132 and 134 may be about 4 centimeters in length.
- Biodegradable central portion 190 may be formed from a
- biodegradable prosthetic material a xenograft, an allograft, or homograft material.
- non-absorbable lateral portions 120 may be formed from a prosthetic material such as polypropylene.
- Non-absorbable lateral portions 120 may contain pores throughout the sheet to allow for tissue integration.
- Biodegradable central portion 190 is configured to maintain its structural integrity until the patient's tissue has had sufficient time to fixate onto nonabsorbable lateral portions 120 through fibrosis, as well as cause the fibrosis of the biodegradable central portion 190. In certain configurations, biodegradable central portion 190 is designed to lose its structural integrity between one to twelve months.
- biodegradable central portion 190 is designed to degrade in about one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve months.
- Structural integrity is the point when the absorbable or biodegradable central portion 190 of the hybrid surgical graft 100 is no longer supporting the previously prolapsed area.
- FIGs. 2 and 3 show additional configurations employing various aspects of the invention.
- Each of the configurations shown in FIGs. 2 and 3 include permanent, non- absorbable lateral portions on either side of the biodegradable or absorbable central portion.
- a hybrid surgical graft 200 in accordance with certain aspects of the invention may be provided with biodegradable central portion 210 attached along its long side edges to non-absorbable lateral side portions 230 (with preferably one or more arms 232 and 234 extending outward from non-absorbable lateral portions 230 to attach the hybrid surgical graft 200 to the pelvic sidewall), along its top edge to a permanent, non-absorbable anterior bridge 236, and along its bottom edge to permanent, non-absorbable posterior bridge 238, such that the entire perimeter of biodegradable central portion 210 is in contact with a section of non-absorbable material.
- annular ring of permanent, non- absorbable material will remain to provide continued support to the patient's vaginal walls, but with minimized risk of healing abnormalities or complications in the region that was initially covered by central bio degradable portion 210.
- hybrid surgical graft 300 may be provided with biodegradable central portion 390 attached along its long side edges to non-absorbable lateral side portions 330 (with preferably one or more arms 332 and 334 extending outward from non-absorbable lateral portions 330 to attach the hybrid surgical graft 300 to the pelvic sidewall), along its top edge to a permanent, non-absorbable anterior bridge 336 of increased width, and along its bottom edge to permanent, non-absorbable posterior bridge 338, such that the entire perimeter of biodegradable central portion 390 is again in contact with a section of non-absorbable material.
- a reinforced annular ring of permanent, non-absorbable material will remain to provide continued support to the patient's vaginal walls, but with minimized risk of healing abnormalities or complications in the region that was initially covered by central bio degradable portion 390.
- Anterior and posterior non-absorbable bridges 236 and 238 of FIG. 2 may have a width of approximately 1mm, while anterior and posterior non-absorbable bridges 336 and 338 of FIG. 3 may have a width of approximately 2mm.
- such dimensions are exemplary, and those of ordinary skill in the art will recognize that the width of such bridges may be increased or decreased to provide greater or less reinforcement to the resulting annular ring of permanent, non-absorbable material as a particular patient's condition may warrant, all without departing from the spirit and scope of the invention.
- the widths of the lateral and bridge portions are less than the length dimension along the major axis of the absorbable or degradable central portion.
- the width of the absorbable or bio-degradable central portion is between approximately 0.5 centimeters and 5 centimeters. In certain configurations, the width of the central portion is about one, two, three, four, or five centimeters. The length of the central biodegradable portion
- the length of the central biodegradable portion can be about three, four, five, six, seven, eight, nine, or ten centimeters.
- permanent non-absorbable lateral portions and bridge portions are formed of a polypropylene non-absorbable mesh having a filament diameter of preferably 0.5 mm - 1 mm, and more preferably about 0.15 mm, and the absorbable or biodegradable central portion is formed as a sagittal section of the hybrid surgical graft from a biodegradable prosthetic material, such as polydioxanone (PDO).
- PDO polydioxanone
- the PDO fiber that is used to create the absorbable or bio-degradable mesh may have a filament diameter of between about 0.1 mm to about 4 mm.
- the preferred diameter of the PDO fiber will depend on the desired resorption time. Those skilled in the art will recognize that the larger the diameter of the PDO fiber, the longer the PDO mesh will remain in the body. A person having ordinary skill in the art will likewise be able to determine the appropriate mesh thickness for each patient depending upon the patient's specific condition.
- the weave pattern or other configuration for the meshes of a hybrid surgical graft formed as disclosed herein may be configured in any manner known to those of ordinary skill in the art. In one particular configuration, a warp knitting configuration may be used.
- PDO #5-0 USP Suture Material may be used to form the central biodegradable portion, and PP- polypropylene monofilament with a diameter of 0.15 mm may be used to form the nonabsorbable portion lateral and bridge portions of the hybrid surgical graft.
- Each material may be warp knitted.
- the differing materials are preferably attached by wale stitches made of PDO.
- the tail of the graft is first cut to fit the patient's vagina.
- the fitted hybrid surgical graft is then inserted into the patient's vagina and set into place beneath the prolapsed area.
- sutures may be used to attach the one or more arms to the pelvic sidewall, muscles, or ligaments. The arms are then adjusted to set the graft in place. Fixation means other than sutures may be suitable and used in various situations as will occur to those of ordinary skill in the art.
- Yarn/Fiber PDO #5-0 USP Suture Material (Blue); PP-polypropylene monofilament diameter 0.006" (.15mm)
- Knitting PDO lateral section consist of 7 wale stitches in width made up of PDO. 1 wale stitch on either side of 7 PDO wale stitches is described as the transitional zone. Transitional zone is alternating PDO and PP stitches. Adding all area in the PDO lateral section total is 9 wales in width.
- FIGS. 4-5 Images of the prepared samples are shown in FIGS. 4-5.
- Macroporous non-absorbable monofilament meshes commonly used for the treatment of pelvic organ prolapse are often associated with problems related to their exposure or erosion into the vagina.
- a mesh has been designed in accordance with certain aspects of an embodiment of the invention to avoid these problems by incorporating a central portion composed of absorbable mesh.
- a prototype hybrid mesh sheet is provided consisting of two parallel panels of non-absorbable filament material separated by a central panel of absorbable filament (FIG. 4).
- the placement of both types of mesh was easily accomplished.
- the hybrid mesh tended to curl along the two edges perpendicular to the direction of the central stripe.
- the model was capable of forming peri-vaginal adhesions on the anterior side to a standard polypropylene mesh. Adhesions to the posterior side were usually sparse. At 6 and 13 weeks, the extent of adhesions in Prolene mesh animals was generally slightly lower than in hybrid mesh-treated animals. This trend was reversed at 26 weeks.
- Hybrid meshes were produced by Mark A. Sunderland, Manager Academic Operations, Textile Engineer and Strategist Kanbar College-Design Engineering and Commerce, Philadelphia University 4201 Henry Avenue, Philadelphia, PA 19144. The meshes were supplied as individually packed and sterilized sheets approximately 9 x 5.5 cm. Running the length of the mesh was the central strip of knitted, dyed polydioxanone 1.5cm in width. Knitted into this strip on either side were strips of polypropylene, about 2cm wide. Meshes were sterilized by Ethylene Oxide by Isomedix, STERIS Isomedicx Services, 3459 South Clinton Avenue, NJ 07080.
- PROLENE Soft Polypropylene Mesh (Non-absorbable synthetic surgical mesh) was obtained from Ethicon, Inc., (Somerville, NJ) as a 10 x 10" mesh.
- Product Code SPLI Lot DAB333, expiry date Jan 2016. The mesh consisted of alternating stripes of undyed (about 1.7cm) and blue-dyed (about 4mm) polypropylene.
- Group Assignments There were two groups, each of 9 animals.
- Group A (Control) treatment performed with Prolene Mesh.
- Group B (Test) treatment performed with novel hybrid mesh. Three animals from each group were evaluated at approximately 42, 91 and 182 days.
- the placement of both types of mesh was easily accomplished.
- the hybrid mesh tended to curl along the two edges perpendicular to the direction of the central stripe.
- Macroporous non-absorbable monofilament meshes commonly used for the treatment of pelvic organ prolapse are often associated with problems related to their exposure or erosion into the vagina.
- a mesh has been provided in accordance with certain aspects of an embodiment of the invention to avoid these problems by incorporating a central portion composed of absorbable mesh.
- SYN1401MZV the gross effects of this novel mesh were evaluated in a rabbit model. Tissue specimens were collected in that study but not analyzed.
- Tissue specimens were generated in study SYN1401MZV after surgical fixation in rabbits of one of two kinds of mesh to the uterine ligament over the vagina on both its anterior and posterior surfaces.
- the two meshes were A) Prolene Soft Polypropylene Mesh (Ethicon, Somerville, NJ), or B) a novel hybrid mesh composed of polypropylene with a central portion of polydioxanone (as shown in Fig. 8). Meshes were sutured in place.
- Three animals from each group were evaluated at approximately 6, 13 and 26 weeks after surgery. Upon harvest the anterior surface was marked using a suture for orientation purposes.
- Tissues were fixed in neutral buffered formalin and an approximately 15 x 40 mm rectangle trimmed to include a portion of the vagina and right uterine ligament. Dye was used to identify the anterior and posterior surfaces after sectioning. Tissues were processed using standard techniques. Two sets of three serial sections were taken approximately 5mm from the edge of the trimmed tissue. In each set, one section was stained with H&E, one with trichrome and one section was left unstained. The sections were examined by a veterinary pathologist and evaluated for evidence of tissue reaction, fibrosis, material degradation and foreign body reaction.
- the patterns of inflammatory changes shown for polypropylene whether in the lateral region of the hybrid mesh, or in the lateral and central regions of the Prolene mesh, are essentially similar. Scores remained mild to moderate until 13 weeks and increased a little at 26 weeks. For the hybrid mesh, the inflammatory reaction to the polypropylene portion remained low. Inflammation for the PDS in the central portion of the hybrid mesh shows a different pattern with an initially stronger reaction, attenuating with time.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462034249P | 2014-08-07 | 2014-08-07 | |
PCT/US2015/044299 WO2016022968A1 (en) | 2014-08-07 | 2015-08-07 | Hybrid surgical mesh |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3177230A1 true EP3177230A1 (en) | 2017-06-14 |
EP3177230A4 EP3177230A4 (en) | 2018-04-11 |
Family
ID=55264661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15830588.8A Withdrawn EP3177230A4 (en) | 2014-08-07 | 2015-08-07 | Hybrid surgical mesh |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3177230A4 (en) |
CA (1) | CA2956958A1 (en) |
WO (1) | WO2016022968A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS277367B6 (en) * | 1990-12-29 | 1993-01-13 | Krajicek Milan | Three-layered vascular prosthesis |
US6306079B1 (en) * | 1999-12-07 | 2001-10-23 | Arnaldo F. Trabucco | Mesh pubovaginal sling |
US7771345B1 (en) * | 2002-12-03 | 2010-08-10 | O'donnell Pat D | Surgical instrument for treating female urinary stress incontinence |
US9498322B2 (en) * | 2004-03-31 | 2016-11-22 | Cook Medical Technologies Llc | Multi-portion endoluminal prosthesis |
US20080234543A1 (en) * | 2007-03-23 | 2008-09-25 | Jjamm, Llc | Surgical devices and method for vaginal prolapse repair |
US20110077456A1 (en) * | 2009-09-30 | 2011-03-31 | Bruce Drummond | Prolapse repair device and methods of use |
US20130103079A1 (en) * | 2011-10-24 | 2013-04-25 | Novo Contour, Inc. | Biomimetic multiple strand fiber mesh and sutures |
FR2995779B1 (en) * | 2012-09-25 | 2015-09-25 | Sofradim Production | PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION |
-
2015
- 2015-08-07 WO PCT/US2015/044299 patent/WO2016022968A1/en active Application Filing
- 2015-08-07 EP EP15830588.8A patent/EP3177230A4/en not_active Withdrawn
- 2015-08-07 CA CA2956958A patent/CA2956958A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016022968A1 (en) | 2016-02-11 |
CA2956958A1 (en) | 2016-02-11 |
EP3177230A4 (en) | 2018-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10492897B2 (en) | Implants with absorbable and non-absorbable features for the treatment of female pelvic conditions | |
US9204953B2 (en) | Biocompatible surgical scaffold with varying stretch | |
US9078731B2 (en) | Method for making a knitted mesh | |
US9204954B2 (en) | Knitted scaffold with diagonal yarn | |
US20140277000A1 (en) | Implantable silk prosthetic device and uses thereof | |
EP2900172A1 (en) | Prosthesis comprising a mesh and a strengthening means | |
AU2018200733A1 (en) | Biodegradable articles and methods for treatment of pelvic floor disorders including extracellular matrix material | |
US20170231739A1 (en) | Hybrid surgical mesh | |
EP3177230A1 (en) | Hybrid surgical mesh | |
KR20200143496A (en) | Method for making a lightweight quadriaxial surgical mesh | |
US20100198236A1 (en) | Surgical Meshes and Methods of Use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170131 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180309 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61F 2/00 20060101AFI20180306BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190809 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20191220 |